Photocure ASA Reports Strong Growth for First Quarter of 2026

Photocure ASA, a leading company in bladder cancer solutions, recently released its financial results for the first quarter of 2026, showcasing a remarkable performance that exceeded expectations. The report revealed revenues of NOK 139.0 million from its flagship products Hexvix® and Cysview®, marking an increase from NOK 125.3 million in the same period last year. This growth trajectory highlights the company’s commitment to innovation and excellence in the realm of urology.

Dan Schneider, the President and CEO of Photocure, expressed optimism regarding the company’s performance, stating that performance was especially strong in North America and Europe. The adoption of blue-light cystoscopy continues to gain momentum, contributing to the increased procedural penetration in critical markets. Schneider emphasized that Photocure remains focused on its commercial and strategic priorities, indicating the positive outlook for the rest of the year.

The overall revenue for the first quarter of 2026 climbed to NOK 264.6 million, significantly higher than NOK 125.3 million in Q1 2025. The revenue also included milestone payments totaling NOK 125.6 million for the approval of Cevira in China and the acceptance of the marketing authorization application in Europe. This financial success is underpinned by an adjusted EBITDA of NOK 15.3 million, more than doubled from NOK 9.7 million in the previous year.

One of the key factors in Photocure's ongoing expansion is its ability to deploy new technology efficiently. In Q1 2026, the company installed 11 new Saphira towers in the U.S., enhancing its capacity to deliver innovative solutions. The total number of active accounts in the U.S. climbed by 21% to 413, illustrating the growing trust and reliance on Photocure’s products. Additionally, across Europe, 75 Olympus Visera Elite III systems capable of blue-light cystoscopy have been established since their launch.

Regulatory updates from the FDA have paved the way for significant advancements in blue-light cystoscopy technologies. Specifically, the proposed reclassification process for diagnostic endoscopic light source systems could radically transform the regulatory landscape for these devices in the U.S. Schneider noted that such regulatory clarity is essential for expanding market opportunities and driving deeper penetration.

Photocure’s partners also hit notable milestones—evidence of this includes the April approval of the System Blue BLC platform in China, set to be marketed alongside Hexvix. This achievement aligns perfectly with the company's strategic efforts and signifies increased collaboration in the diagnostics segment.

In addition to enhancing its product offerings, Photocure is broadening its diagnostics strategy. Recently, the company made a strategic investment of $3.0 million in Vesica Health, a firm working on an innovative multi-omic urine biomarker test for early bladder cancer detection. Such initiatives are part of a larger effort to integrate technologies that enhance personalized and data-driven care pathways in uro-oncology.

With a focus on procedural adoption and increased utilization of its products, Photocure is well-positioned for sustained growth. The continued upgrade cycles to next-generation imaging systems and the FDA's anticipated reclassification are expected to bolster the company’s competitive edge.

Looking ahead, Schneider remains confident in Photocure's trajectory, expecting a revenue growth of 7% to 11% on a constant currency basis throughout 2026. Moreover, as the company optimizes its operations, further improvements in its adjusted EBITDA margin are anticipated.

Overall, Photocure ASA is setting a powerful precedent in bladder cancer management. With strategic expansions, innovative product offerings, and increasing market adoption, the company is poised to continue its growth and significantly impact patient care moving forward. Many eyes will be watching how these developments unfold in the quarters ahead, marking a potentially transformative period for both Photocure and the field of urology.